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Background: Vascular smooth muscle cells (VSMCs) of the arterial wall play a critical role in the development of
occlusive vascular diseases. Cysteine-rich protein 2 (CRP2) is a VSMC-expressed LIM-only protein, which functionally
limits VSMC migration and protects against pathological vascular remodeling. The multifunctional cytokine TGFβ
has been implicated to play a role in the pathogenesis of atherosclerosis through numerous downstream signaling
pathways. We showed previously that TGFβ upregulates CRP2 expression; however, the detailed signaling mechanisms
remain unclear.
Results: TGFβ treatment of VSMCs activated both Smad2/3 and ATF2 phosphorylation. Individually knocking down
Smad2/3 or ATF2 pathways with siRNA impaired the TGFβ induction of CRP2, indicating that both contribute to CRP2
expression. Inhibiting TβRI kinase activity by SB431542 or TβRI knockdown abolished Smad2/3 phosphorylation but did
not alter ATF2 phosphorylation, indicating while Smad2/3 phosphorylation was TβRI-dependent ATF2 phosphorylation
was independent of TβRI. Inhibiting Src kinase activity by SU6656 suppressed TGFβ-induced RhoA and ATF2 activation
but not Smad2 phosphorylation. Blocking ROCK activity, the major downstream target of RhoA, abolished ATF2
phosphorylation and CRP2 induction but not Smad2 phosphorylation. Furthermore, JNK inhibition with SP600125 reduced
TGFβ-induced ATF2 (but not Smad2) phosphorylation and CRP2 protein expression while ROCK inhibition blocked JNK
activation. These results indicate that downstream of TβRII, Src family kinase-RhoA-ROCK-JNK signaling pathway mediates
TβRI-independent ATF2 activation. Promoter analysis revealed that the TGFβ induction of CRP2 was mediated through
the CRE and SBE promoter elements that were located in close proximity.
Conclusions: Our results demonstrate that two signaling pathways downstream of TGFβ converge on the CRE and SBE
sites of the Csrp2 promoter to cooperatively control CRP2 induction in VSMCs, which represents a previously
unrecognized mechanism of VSMC gene induction by TGFβ.
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Vascular smooth muscle cells (VSMCs) in the tunica media
of the arteries play important roles in regulating blood pres-
sure and vascular tone. In normal vessels, these VSMCs
exhibit a quiescent and differentiated phenotype and ex-
press proteins involved in the contractile functions such as* Correspondence: syet@nhri.org.tw
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However, in contrast to striated muscle cells, adult VSMCs
retain significant plasticity, known as phenotypic modula-
tion. In response to arterial injury, VSMCs de-differentiate,
downregulate SM marker genes, and change to a prolifera-
tive and migratory phenotype, leading to lesion formation
and occlusive vascular disease [1]. Thus, preventing this de-
differentiation might be a potential therapeutic strategy for
treating vascular disease.
Cysteine-rich protein (CRP) 2, a LIM-only CRP fam-
ily member [2], is highly expressed in VSMCs [3,4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CRP2 expression [3,4], suggesting a critical role for
CRP2 in the response to vascular injury. By gene dele-
tion experiments, we demonstrated that a lack of CRP2
enhanced VSMC migration into the intima and in-
creased neointima formation following arterial injury
[4]. Our recent study determined that CRP2 sequesters
the scaffold protein p130Cas at focal adhesions, con-
trols lamellipodia formation and reduces cell motility.
These CRP2-p130Cas complexes function to blunt
VSMC migration [5]. Therefore, maintaining or upregu-
lating CRP2 expression during vascular injury might serve
as a protective mechanism against intimal thickening.
The multifunctional cytokine TGFβ contributes to the
pathogenesis of atherosclerosis and restenosis [1,6]. During
progressive intimal thickening following balloon angio-
plasty, neointimal SMCs produce TGFβ and it acts as a
growth regulatory factor [6]. The importance of this auto-
crine TGFβ pathway in vascular disease was established
through studies selectively inhibiting TGFβ mRNA in a rat
vascular injury model in vivo, which resulted in blunted
neointimal formation [7]. Some of the effects of TGFβ in
VSMCs are controversial. For example, serum concentra-
tions of active TGFβ are significantly reduced in patients
with advanced atherosclerosis, suggesting TGFβ is a key in-
hibitor of atherosclerosis [8]. TGFβ stimulates SMC differ-
entiation marker gene expression [1,9,10] and inhibition of
TGFβ signaling using neutralizing anti-TGFβ antibodies ac-
celerates the development of atherosclerotic lesions in
apoE-deficient mice [11]. Further supporting a protective
role of TGFβ against vascular lesion formation, targeted
disruption of TGFβ-Smad3 signaling enhances neointimal
hyperplasia after arterial injury [12].
We identified in a previous study that TGFβ induces
CRP2 expression in VSMCs and TGFβ treatment reduces
wild type but not Csrp2 (mouse CRP2 gene symbol)-defi-
cient VSMC migration, demonstrating the functional im-
portance of CRP2 induction by TGFβ in regulating VSMC
migration [13]. TGFβ upregulates CRP2 expression via a
CRE promoter element and transcription factor ATF2 [13];
however, the detailed signaling mechanisms underlying
TGFβ induction of CRP2 remain unclear. The goal of the
present study was to delineate the signaling pathways by
which TGFβ upregulates CRP2 expression, which might
provide an opportunity for developing targeted strategies to
reduce intimal thickening.
Results
TGFβ induces CRP2 expression through Smad2/3 and ATF2
To investigate the signaling pathways that mediate CRP2
induction by TGFβ, we first examined type I TGFβ
receptor (TβRI) downstream signaling. We pretreated
VSMCs with vehicle or TβRI kinase inhibitor SB431542
for 30 min, followed by stimulation with or withoutTGFβ for 24 h and then examined CRP2 expression
levels. SB431542 significantly reduced TGFβ-induced
CRP2 expression (Figure 1A), indicating TβRI kinase ac-
tivity is required for TGFβ induction of CRP2. It is well
established that Smad2/3 transmits TGFβ signaling [14],
thus we examined Smad2/3 activation. Indeed, TGFβ
increased phosphorylation levels of Smad2 and Smad3
in VSMCs (Figure 1B). In addition, as previously re-
ported [13], TGFβ also increased ATF2 phosphorylation
(Figure 1B). Interestingly, SB431542 blocked TGFβ-
induced activation of Smad2 and Smad3 but did not
block ATF2 phosphorylation (Figure 1B). PI3K has also
been implicated in TGFβ signaling [15], thus we deter-
mined whether PI3K pathways participate in this regulation
by treating cells with PI3K inhibitors. Wortmannin or
LY294002 did not affect ATF2 or Smad2/3 phosphorylation
(Figure 1B). These results suggest that in VSMCs, TβRI
mediates TGFβ activation of Smad2/3 whereas neither
TβRI kinase activity nor PI3K signaling is involved in TGFβ
dependent stimulation of ATF2. To define the role of
Smad2/3 and ATF2 in CRP2 upregulation, we used siRNA
to suppress their expression. In comparison with control
siRNA, knockdown of Smad2/3 or ATF2 abrogated TGFβ-
induced CRP2 expression (Figure 1C-D), supporting the
concept that both Smad2/3 and ATF2 contribute to CRP2
induction.
ATF2 activation by TGFβ is independent of TAK1 and TRAF6
It has been shown in epithelial cells and fibroblasts that in-
dependent of TβRI kinase activity, TGFβ activates TAK1
signaling through interaction of TβRI with TRAF6, whereas
Smad2 activation is not dependent on TRAF6 [16,17].
Thus, we examined whether TGFβ activates ATF2 through
TAK1 and TRAF6 in VSMCs. We transfected VSMCs with
siRNA to TAK1 or TRAF6, or control siRNA and then
stimulated cells with or without TGFβ for 10 min. Western
blot analysis showed that knocking down TAK1 did not
alter ATF2 activation although it partially reduced Smad2
phosphorylation (Figure 2A), indicating TAK1 was not in-
volved in TGFβ-induced ATF2 phosphorylation in VSMCs.
TRAF6 knockdown did not affect TGFβ-induced ATF2 or
Smad2 phosphorylation (Figure 2B). Moreover, knocking
down TRAF6 did not abrogate TGFβ induction of CRP2
protein expression after 24 h (Figure 2C).
TβRI kinase-independent ATF2 activation by TGFβ
Upon ligand binding, TβRII recruits TβRI into an active
heterotetrameric signaling complex and transphosphory-
lates TβRI to activate its kinase function [18]. TβRI can
then phosphorylate Smad2/3 for TGFβ signaling. Inter-
estingly, we found that inhibiting TβRI kinase activity
blocked TGFβ-induced Smad2/3 but not ATF2 activation
(Figure 1B). This ATF2 phosphorylation is not mediated


















































































































Figure 1 TGFβ induces CRP2 expression through Smad2/3 and ATF2. (A) TβRI kinase activity contributes to CRP2 induction. VSMCs were
pretreated with vehicle or TβRI kinase inhibitor SB431542 (10 μM) for 30 min before stimulation with TGFβ (10 ng/ml) for 24 h. Total proteins
were then harvested for Western blot analysis to detect CRP2 expression. SB431542 significantly decreased TGFβ-induced CRP2 expression. Values
are mean ± S.E. of at least three experiments. *P < 0.05 vs. control (− TGFβ); #P < 0.05 vs. TGFβ-stimulated vehicle group. (B) TβRI kinase activity is
required for activation of Smad2/3 but not ATF2. VSMCs were pretreated with vehicle, SB431542, PI3K inhibitor Wortmannin (1 μM), or LY294002
(10 μM) for 30 min prior to stimulation with or without TGFβ for 15 min. Activation of Smad2/3 and ATF2 was then determined with Western blot
analysis. (C-D) VSMCs were transfected with 20 nM control siRNA, Smad2/3 siRNA (C) or ATF2 siRNA (D) using Lipofectamine RNAiMAX transfection
reagent and then stimulated with or without TGFβ for 24 h. Western blot analysis was performed to detect CRP2, Smad2/3, or ATF2 levels.
The membranes were subsequently probed with actin for loading control. Values are mean ± S.E. of at least three experiments. #P < 0.05 vs.
TGFβ-stimulated siControl group.
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down TβRI expression using siRNA. Silencing of TβRI ab-
rogated TGFβ-induced Smad2 phosphorylation but not
ATF2 phosphorylation (Figure 3A), suggesting indeed TβRI
is not required for TGFβ-induced ATF2 activation.
Type III TGFβ receptor (TβRIII) has been demon-
strated to bind and present TGFβ to type II TGFβ recep-
tor (TβRII), thereby increases type II receptor binding
affinity and cell responsiveness to TGFβ [19]. To deter-
mine whether TβRIII participates in the ATF2 activation,
we knocked down TβRIII levels in VSMCs by TβRIII
siRNA, cells were then stimulated with or without
TGFβ. Compared with control siRNA, knocking downTβRIII levels did not affect the activation of ATF2 or
Smad2 at the 10 min early time point (Figure 3B) or af-
fecting CRP2 protein expression 24 h later (data not
shown). These results suggest that TβRIII did not affect
TGFβ signaling in the CRP2 induction. We then
knocked down TβRII expression by siRNA and exam-
ined phosphorylation of these signaling molecules. Silen-
cing TβRII not only reduced ATF2 activation but also
that of Smad2 (Figure 3C), indicating the critical import-
ance of TβRII in mediating TGFβ signaling. To further
assess the role of TβRII, we transfected VSMCs with a
dominant-negative type II receptor HA-TβRII(ΔCyt)




























Figure 2 Neither TAK1 nor TRAF6 mediates TGFβ-induced ATF2
activation. VSMCs were transfected with 20 nM TAK1 siRNA (A) or
TRAF6 siRNA (B) using Lipofectamine RNAiMAX transfection reagent
and then stimulated with or without TGFβ for 10 min. Control siRNA
was also transfected as a control. Western blot analysis was performed
to detect TAK1, TRAF6, and phosphorylation of ATF2 and Smad2. The
membranes were subsequently probed with actin for loading control.
(C) VSMCs were transfected with control or TRAF6 siRNA and then
treated with or without TGFβ for 24 h. Total proteins were then
isolated for Western blot analysis to detect TRAF6 and CRP2 expression.
The membranes were subsequently probed with actin for loading
control. Representative blots of at least three independent
experiments are shown.
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phorylating and activating the type I receptor. Interest-
ingly, TβRII(ΔCyt) attenuated Smad2 phosphorylation asexpected but not the activation of ATF2 (Figure 3D). In
addition, TβRII(ΔCyt) attenuated TGFβ-induced CRP2
expression 24 h later (Figure 3E).
Src family kinase mediates TβRII-dependent TGFβ activation
of RhoA-ROCK and ATF2 in VSMCs
We next investigated how TβRII mediates ATF2 activation
independent of TβRI in VSMCs. In JEG3 choriocarcinoma
cells, Src kinase is involved in TGFβ-induced early signaling
[21]. In addition, c-Src has been reported to mediate TGFβ-
induced SMC gene expression [22]. We therefore examined
whether in VSMCs Src activation was required to transmit
TGFβ signaling for ATF2 activation. The selective Src fam-
ily kinase inhibitor SU6656 dose dependently abrogated
TGFβ-induced ATF2 activation (Figure 4A). In contrast,
SU6656 did not alter Smad2 phosphorylation by TGFβ
even at high doses (Figure 4A). These data indicate that Src
family kinase functions downstream of TβRII in transdu-
cing Smad-independent TGFβ signaling to activate ATF2.
Since rapid Src activation by TGFβ has been found to ef-
fectively activate Small GTPase RhoA in other cell systems
[21], we then examined whether in VSMCs RhoA was
activated downstream of Src family kinase. Indeed, TGFβ
enhanced RhoA activation and SU6656 inhibited TGFβ-
induced RhoA activation (Figure 4B). Furthermore, trans-
fection of VSMCs with control or RhoA siRNA revealed
that RhoA knockdown attenuated TGFβ-induced ATF2 ac-
tivation but not that of Smad2 (Figure 4C). In addition,
siRNA-mediated silencing of RhoA not only decreased acti-
vation of the signaling molecules at the early time point
(Figure 4C) but also reduced TGFβ-induced CRP2 protein
expression after 24 h (Figure 4D). These results suggest
that Src family kinase-RhoA signaling mediates TβRII-
dependent ATF2 activation and CRP2 expression by TGFβ.
Since RhoA kinase (ROCK) is a major target of RhoA
and that ROCK has been implicated in SMC differenti-
ation by modulating TGFβ-Smad signaling [23], we ex-
amined whether ROCK functioned downstream of RhoA
to regulate ATF2 activation. Interestingly, treatment of
VSMCs with ROCK inhibitor Y-27632 abolished ATF2
phosphorylation but not that of Smad2 (Figure 5A). Sup-
porting this notion, Y-27632 abrogated TGFβ-induced
CRP2 protein expression after 24 h (Figure 5B).
JNK activation is required for TGFβ-induced phosphorylation
of ATF2
Because MAP kinase pathways have been shown to
contribute to TGFβ signaling [24,25], we evaluated ac-
tivation of MAP kinase pathway in ATF2 phosphoryl-
ation. TGFβ increased phosphorylation of JNK, p38,
and ERK1/2 (Figure 6A). However, kinase inhibitor
studies revealed that JNK inhibitor SP600125 but not
p38 MAP kinase inhibitor SB203580 or ERK inhibitor
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Figure 3 Type II TGFβ receptor is crucial in mediating TGFβ-induced ATF2 signaling. (A-C) VSMCs were transfected with 20 nM control
siRNA or siRNA to different types of TGFβ receptors. Following 24 h recovery in growth media and 24 h serum-starvation, cells were stimulated
with or without TGFβ for 10 min. Western blot analysis was performed to detect different TGFβ receptor expression levels and phosphorylation of
Smad2 and ATF2. (A) TβRI knockdown inhibits Smad2 phosphorylation but not that of ATF2. #P < 0.05 vs. TGFβ-stimulated siControl group. (B)
TβRIII knockdown does not affect TGFβ activation of ATF2 or Smad2. (C) TβRII knockdown attenuates TGFβ activation of ATF2 and Smad2.
#P < 0.05 vs. TGFβ-stimulated siControl group. (D) Dominant-negative TβRII (DN-TβRII) impairs Smad2 but not ATF2 activation. VSMCs
were electroporated with control vector or HA-tagged DN-TβRII (HA-TβRII(ΔCyt)) and then stimulated with or without TGFβ for 10 min.
Western blot analysis was performed to assess phosphorylation of Smad2 and ATF2. Overexpression of DN-TβRII was evaluated by
probing Western blots with HA antibody. #P < 0.05 vs. TGFβ-stimulated vector control group. (E) DN-TβRII impairs TGFβ-induced CRP2
induction. VSMCs were electroporated with control vector or HA-TβRII(ΔCyt) and stimulated with TGFβ for 24 h. Total proteins were
then isolated for Western blot analysis to detect CRP2 protein levels. The blots were then probed with HA antibody to detect HA-TβRII(ΔCyt) expression.
#P< 0.05 vs. TGFβ-stimulated vector control group. The membranes were subsequently probed with actin for loading control. Representative blots of at
least three independent experiments are shown.
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Figure 4 Src family kinase mediates TβRII-dependent TGFβ activation of RhoA and ATF2 in VSMCs. (A) Src family kinase inhibitor SU6656
dose-dependently reduces TGFβ activation of ATF2 but not that of Smad2. VSMCs were pretreated with increasing concentrations of SU6656 for
30 min and then stimulated with TGFβ for 10 min. Phosphorylation of ATF2 and Smad2 was determined by Western blot analysis. The membranes
were subsequently probed with actin for loading control. #P < 0.05 vs. TGFβ-stimulated but without SU6656 treatment group. (B) SU6656 abolishes
TGFβ-induced RhoA activation. VSMCs were pretreated with 5 μM SU6656 for 30 min prior to stimulation with TGFβ for 10 min. RhoA activation was
then determined by GST-Rhotekin-RBD assays. GTP-RhoA was subsequently eluted and subjected to Western blot analysis with an anti-RhoA antibody.
To verify equal loading, 15 μg of cell lysates were run on separate gels and blots probed with an anti-RhoA antibody for total RhoA. *P< 0.05 vs. control
(− TGFβ and – SU6656); #P< 0.05 vs. TGFβ-stimulated vehicle group. (C) RhoA knockdown reduces TGFβ activation of ATF2 but not Smad2. VSMCs were
transfected with 20 nM control siRNA or RhoA siRNA and then stimulated with or without TGFβ for 10 min. Western blot analysis was performed to detect
RhoA and phosphorylation of ATF2 and Smad2. #P < 0.05 vs. TGFβ-stimulated siControl group. (D) RhoA knockdown reduces TGFβ-induced
CRP2 expression. VSMCs were transfected with 20 nM control siRNA or RhoA siRNA and then stimulated with or without TGFβ for 24 h.
Western analysis was performed to detect RhoA and CRP2 protein levels. The membranes were subsequently probed with actin for loading
control. #P < 0.05 vs. TGFβ-stimulated siControl group. Representative blots of at least three independent experiments are shown.
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Smad2 phosphorylation (Figure 6B). To determine whether
JNK inhibition ultimately affected CRP2 induction by
TGFβ, we first pretreated VSMCs with vehicle or SP600125
for 30 min, stimulated with or without TGFβ for 24 h, then
examined CRP2 expression levels. TGFβ induced CRP2
protein levels while SP600125 significantly reduced CRP2
levels (Figure 6C), suggesting JNK functions upstream of
ATF2 to mediate CRP2 induction. Since unphosphorylated
ATF2 is transcriptionally inactive, we overexpressed aconstitutively active C2/ATF2 construct in VSMCs and ex-
amined CRP2 expression levels. Indeed, overexpression of
C2/ATF2 increased CRP2 protein 1.5-fold (vs. vector con-
trol, P < 0.05) (Figure 6D). Furthermore, C2/ATF2 rescued
the TGFβ induction of CRP2 that was inhibited by JNK in-
hibitor SP600125 (Figure 6E), demonstrating the import-
ance of JNK-ATF2 pathway in TGFβ-mediated CRP2
induction. We next wanted to determine whether JNK
functioned downstream of ROCK in the signaling pathway
leading to ATF2 activation. Indeed, Y-27632 abrogated







































































Figure 5 ROCK mediates Smad-independent ATF2 activation
by TGFβ. (A) VSMCs were pretreated with vehicle or ROCK inhibitor
Y-27632 (10 μM) for 30 min before stimulation with TGFβ for 10 min.
Western blot analyses were then performed to examine phosphorylation
of ATF2 and Smad2. #P< 0.05 vs. TGFβ-stimulated vehicle group. (B)
VSMCs were pretreated with vehicle or Y-27632 for 30 min before
stimulation with or without TGFβ for 24 h. CRP2 expression was
detected by Western blot analysis. #P < 0.05 vs. TGFβ-stimulated
vehicle group. Representative blots of at least three independent
experiments are shown.
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JNK-ATF2 signaling axis.
Both SBE and CRE sites are functionally important for
basal and TGFβ induction of the Csrp2 promoter activity
It is evident from our studies that Smad2/3 and ATF2 par-
ticipate in the TGFβ induction of CRP2. As ATF2 activates
Csrp2 transcription via CRE site [13], we set out to identify
elements that are responsible for Smad2/3-mediated
induction. Examination of the sequences within the
mouse −795 bp Csrp2 promoter (which is responsive
to TGFβ) revealed that in addition to the previously
identified CRE site at bp −461 (Figure 7A, italic and
underlined) there are two potential Smad binding ele-
ments (SBE), located at bp −681 and −445 (Figure 7A,
bold and underlined), each with a base divergent from
the consensus SBE (5′-GTCTAGAC-3′). To determine
the potential function of these two putative SBE sites, we
generated SBE mutant luciferase constructs, −795SBE681-
mut and –795SBE445mut, each with 3 bases mutated
within the putative SBE sites (Figure 7B, left). We then
transiently transfected VSMCs with parental wild-type lu-
ciferase plasmid –795Csrp2-luc and mutant constructs.
Mutation of SBE681 did not affect either basal or TGFβ in-
duction of Csrp2 promoter activity (Figure 7B). Similar to
that of CRE mutation, SBE445 mutation not only decreased
basal promoter activity but also reduced TGFβ responsive-
ness (Figure 7B). Double mutation of CRE and SBE445 fur-
ther reduced promoter response (Figure 7B). These results
indicate that both the SBE at bp −445 and CRE at −461 are
functionally important in regulating Csrp2 transcription.
Further supporting this notion, these two sites are com-
pletely conserved across species among human, mouse, and
rat (Figure 7C).
To further demonstrate the critical roles of Smad2/3 and
ATF2 in Csrp2 transcriptional regulation, we cotransfected
luciferase plasmid –795Csrp2-luc with expression plasmids
Smad2, C2/ATF2, or both in VSMCs and examined pro-
moter activity. Smad2 slightly increased Csrp2 promoter ac-
tivity (1.5-fold, Figure 7D) although it did not reach a
statistical significance, likely because Smad 2 might be in-
active without TGFβ stimulation. Constitutively active C2/
ATF2 significantly increased Csrp2 promoter activity to
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Figure 6 JNK activation is required for TGFβ-induced ATF2 phosphorylation and CRP2 induction. (A) JNK activation is required for TGFβ-
induced phosphorylation of ATF2 but not Smad2/3. VSMCs were pretreated with vehicle, JNK inhibitor SP600125 (10 μM), p38 inhibitor SB203580
(10 μM), or ERK1/2 inhibitor U0126 (10 μM) for 30 min before stimulation with TGFβ (10 ng/ml). Phosphorylation of ATF2, JNK, p38, and ERK1/2
was determined 15 min after TGFβ stimulation. The membranes were subsequently probed with antibodies against total proteins for ATF2, JNK,
p38, and ERK1/2 for loading control. (B) VSMCs were pretreated with vehicle or SP600125 for 30 min before stimulation with TGFβ. Cell lysates
were harvested at the indicated time points and the phosphorylation of ATF2, JNK, and Smad2 examined. The membranes were subsequently
probed with antibodies against total proteins for ATF2, JNK, and Smad2 for loading control. (C) JNK activity contributes to CRP2 induction. VSMCs
were pretreated with vehicle or SP600125 for 30 min before stimulation with TGFβ for 24 h. Total proteins were then harvested for Western blot
analysis to detect CRP2 expression. Values are mean ± S.E. of at least three experiments. *P < 0.05 vs. control (− TGFβ); #P < 0.05 vs. TGFβ-
stimulated vehicle group. (D) Constitutively active FLAG-C2/ATF2 increases CRP2 expression. VSMCs were electroporated with control vector or
FLAG-C2/ATF2 and total proteins prepared 24 h later. Western blot analysis was performed to assess CRP2 levels. Overexpression of FLAG-C2/
ATF2 was evaluated by probing Western blots with FLAG antibody. (E) Overexpression of FLAG-C2/ATF2 rescues SP600125-inhibited TGFβ induc-
tion of CRP2. VSMCs were electroporated with control vector or FLAG-C2/ATF2, serum-starved, pretreated with vehicle or JNK inhibitor SP600125
for 30 min before stimulation with TGFβ for 24 h. Western blot analysis was performed to assess CRP2 expression. FLAG-C2/ATF2 expression was
evaluated with FLAG antibody. (F) VSMCs were pretreated with vehicle or ROCK inhibitor Y-27632 (10 μM) for 30 min before stimulation with or
without TGFβ for 10 min. Phospho-JNK expression was detected by Western blot analysis. The membranes were subsequently probed with actin
for loading control. *P < 0.05 vs. control (− TGFβ); #P < 0.05 vs. TGFβ-stimulated vehicle group. Representative blots of at least three independent
experiments are shown.
Wu et al. Cell Communication and Signaling 2014, 12:22 Page 8 of 14
http://www.biosignaling.com/content/12/1/22together enhanced Csrp2 promoter activity to 19-fold
(Figure 7D), indicating a synergistic effect of these two
factors. Next, we performed real-time PCR to examine
the effects of Smad2 and C2/ATF2 on CRP2 mRNA
levels. Similar to promoter activity, Smad2 slightly in-
creased while C2/ATF2 increased CRP2 mRNA levels
to 2-fold (Figure 7E). In addition, Smad2 and C2/ATF2
synergistically induced CRP2 mRNA levels (Figure 7E).
Discussion
CRP2 plays a critical role in attenuating the development of
arteriosclerosis [3,4]. Upregulating CRP2 in the injured ar-
tery may protect against neointima formation. The goal of
this study was to identify mechanisms and signaling path-
ways that sustain or upregulate CRP2 expression todecrease vascular disease. We show that activation of both
Smad2/3 and ATF2 are essential for enhancing CRP2 ex-
pression. Unlike the TβRI-dependent Smad pathway, Src
family kinase-RhoA-ROCK-JNK signaling axis mediates
TβRI-independent ATF2 activation. The TGFβ induction of
CRP2 is mediated through the CRE and SBE promoter ele-
ments. Our results demonstrate that two signaling axes
downstream of TGFβ converge on Csrp2 promoter to co-
operatively control CRP2 induction in VSMCs.
Smad proteins function as intracellular TGFβ signaling
effectors. Following activation and translocation into the
nucleus, the heterotrimeric Smad complex recognizes
and binds to SBE site to activate target gene expression
[26]. Consistent with this canonical signaling pathway,




Figure 7 SBE445 and CRE461 are functionally important for basal and TGFβ-induced Csrp2 promoter activity. (A) Two putative SBE sites
at bp −681 and −445 of the mouse Csrp2 promoter (bold and underlined). The CRE site at −461 is also indicated (italic and underlined). (B) The
putative SBE site at −445 and CRE at −461 are important for Csrp2 promoter activity. The −795 Csrp2 wild type and SBE and CRE mutant
promoter constructs are schematically depicted in the left panel. VSMCs were transiently transfected with Csrp2 luciferase reporter constructs
containing −795, SBE681mut, SBE445mut, CREmut, or CREmut/SBE445mut in triplicate using FuGENE 6 transfection reagent. Two hours after
transfection, cells were treated with or without TGFβ (10 ng/ml) for 24 h. Cells were then harvested for luciferase activity and protein assays.
Luciferase activity is expressed relative to −795 without TGFβ treatment. Values are mean ± S.E. of at least three experiments. (C) Conservation of
the CRE and SBE sites among species. Sequence alignment of the corresponding regions of human and rat promoter sequences to the mouse
promoter. The CRE site is in italic and SBE site in bold type. (D) VSMCs were transiently cotransfected with –795Csrp2-luc reporter with empty
vector or expression plasmids Smad2, C2/ATF2, or both. Cells were then harvested 24 h later for luciferase activity and protein assays. Luciferase
activity is expressed relative to −795 with empty expression vector. Values are mean ± S.E. of at least three experiments. *P < 0.05 vs. empty
expression vector. (E) VSMCs were electroporated with control vector or expression plasmids Smad2, C2/ATF2, or both. Total RNA was prepared
12 h later for real-time PCR analysis to assess CRP2 mRNA expression and β-actin was used as an internal control for normalization. Quantification
was performed by the comparative CT method. CRP2 mRNA is expressed relative to empty expression vector. Values are mean ± S.E. of at least
three experiments. *P < 0.05 vs. empty expression vector.
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Csrp2 promoter (Figures 1 and 7). This Smad2/3 activa-
tion is dependent on TβRI and its kinase activity, as
siTβRI or SB431542 inhibited TGFβ-induced Smad2/3
phosphorylation (Figures 1 and 3). TGFβ also activated
ATF2 to induce CRP2 expression ([13] and Figure 1).The fact that ATF2 phosphorylation was not affected ei-
ther by inhibiting TβRI kinase activity or knocking down
TβRI expression (Figures 1B and 3A) indicated that
TβRI was dispensable for ATF2 activation. By con-
trast, TβRII was required for both Smad2 and ATF2 acti-
vation (Figure 3C). Intriguingly, although it was expected
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phorylation (because it lacks cytoplasmic C-terminal kinase
domain and is unable to activate TβRI) DN-TβRII failed to
inhibit ATF2 phosphorylation (Figure 3D). Taken together,
these results suggest that in VSMCs TβRII alone is able to
mediate TGFβ signaling to ATF2 and the cytoplasmic do-
main of TβRII is not required. This TβRI-independent sig-
naling to ATF2 is similar to the findings in dermal cells that
TβRII directly activates ERK1/2 without the participation of
TβRI [27] and supports the notion that TGFβ recep-
tors can activate non-Smad proteins and allow Smad-
independent TGFβ responses [28].
We found JNK functioned upstream of ATF2 in the
TGFβ induction of CRP2 (Figure 6); however, JNK in-
hibition did not affect Smad2/3 activation (Figure 6B).
These results are in contrast to the findings in Mv1Lu
epithelial cells and T98G glioblastoma cells [29,30]. In
epithelial cells, while TGFβ activates both Smad3
and JNK there is an interdependent Smad and JNK sig-
naling because activated JNK in turn phosphorylates
Smad3 [29]. In glioblastoma cells [30], TGFβ activates
p38 MAPK and ATF2 but does not induce JNK phos-
phorylation; furthermore, inhibition of p38 MAPK de-
creases TGFβ-induced phosphorylation of ATF2 and
Smad2. Those findings indicate an interaction between
Smad and p38 MAPK pathways downstream of TGFβ
[30] that are in contrast to our results that p38 MAPK
and ERK1/2 are not involved in ATF2 activation
(Figure 6A). Our current findings and these previous
reports suggest that TGFβ signaling pathways are
likely to be cell type specific.
We demonstrated that both CRE and SBE sites con-
tribute to CRP2 upregulation by TGFβ (Figure 7). Im-
portantly, these two sites are completely conserved
across species among human, mouse, and rat (Figure 7C),
suggesting the critical importance of the CRE and SBE in
the regulation of Csrp2 transcription. The importance of
CRE in mediating TGFβ target gene induction was shown
in a rat intestinal epithelial cell line 4–1 that transcription
factors CREB-1, ATF2, c-Jun, and Smad3 all bind to the
CRE site to activate transcription [31]. Interestingly, ATF2,
via its basic leucine zipper region, was shown to bind to the
MH1 domain of the Smad proteins [32]. TGFβ stimulation
further enhances the association of ATF2 and Smad3/4 and
increases the CRE-containing reporter activity in HepG2
cells [32]. Since blocking either the ATF2-CRE or TβRI-
Smad2/3 axis significantly reduced CRP2 expression
(Figures 1 and 7) and given the proximity of CRE
and SBE sites (8 bp apart), it is possible that Smad
heterotrimer and ATF2 might form a higher order
complex to cooperatively, rather than independently,
regulate CRP2 expression. This regulation via two cis
elements is similar to that of several SMC marker
genes [33]. For example, the TGFβ induction of SM α-actin and SM22α expression is coordinately regulated
by a TGFβ control element (TCE) and nearby CArG
(CC(A/T)6GG) elements in the 5′ promoter [33,34].
However, the regulatory mechanism of CRP2 expres-
sion by TGFβ differ from these SMC marker genes in
that CRP2 induction is mediated through the CRE and
SBE elements whereas TCE and CArG elements medi-
ate the TGFβ induction of SM α-actin and SM22α
expression.
Conclusion
Based on our findings, we propose that two signaling
pathways downstream of TGFβ converge on Csrp2 pro-
moter to cooperatively induce Csrp2 gene transcription and
protein expression (Figures 1, 7, and 8). In the canonical
pathway, upon TGFβ binding, TβRII trans-phosphorylates
TβRI to activate its kinase function, leading to Smad2/3
phosphorylation. Activated Smad2/3 then cooperate with
Smad4 to form a complex, translocates into the nucleus
and bind to SBE of the Csrp2 promoter. In the non-
canonical signaling pathway that does not require TβRI,
TGFβ binds to TβRII and activates Src family kinase and
RhoA signaling. Activated ROCK in turn phosphorylates
JNK, resulting in ATF2 activation. Activated ATF2
dimer then binds to the CRE site 8 bp upstream of SBE
on the Csrp2 promoter. The ATF2 on the CRE site and
Smad proteins on the SBE site might associate to form
a higher order complex to cooperatively enhance CRP2
expression (Figure 8) in VSMCs, which represents a
previously unrecognized mechanism of VSMC gene in-
duction by TGFβ.
Methods
Luciferase reporter and expression constructs
The –795Csrp2-luc luciferase reporter plasmid was de-
scribed previously [35] and used as a template to generate
mutant constructs. Site-directed mutagenesis was per-
formed using Pfu polymerase (Stratagene) to mutate the
putative SBE sites at −681 from GTCTAGAA to CTATC-
GAA and at −445 from GTCTAGAT to CTATCGAT (mu-
tated bases are italicized) to generate SBE681mut and
SBE445mut constructs, respectively. The CREmut/SBE445-
mut construct with double mutations at –461CRE and –
445SBE was generated using –795CREmutCsrp2-luc [13]
as a template to mutate putative –445SBE site as
above. All constructs were confirmed by DNA sequen-
cing. Dominant-negative mutant of type II TGFβ re-
ceptor pCMV5 HA-TβRII(ΔCyt) that lacks C-terminal
kinase domain and is unable to activate TβRI [20] was
obtained from Addgene (plasmid 14051). The expression
plasmid pCMV5-Smad2 has previously been described
[36]. The constitutively active mutant construct FLAG-C2/
ATF2 [37] that contains a FLAG tag at the N-terminus,
followed by the constitutively active activation domain
Figure 8 Schematic model of TGFβ signaling pathways for CRP2 induction in VSMCs. Upon TGFβ stimulation, two signaling axes are
activated: the canonical TβRI-dependent Smad2/3 pathway and the non-canonical ATF2 pathway. In the canonical pathway, activated Smad2/3
form a complex with Smad4, translocates into the nucleus, and binds to SBE site at −445 of the Csrp2 promoter. In the non-canonical pathway,
following TβRII binding of TGFβ, TβRII (without the requirement of TβRII’s cytoplasmic kinase domain) activates Src family kinase (SFK), which in
turn activates RhoA. Enhanced RhoA activation leads to ROCK activation and increased JNK phosphorylation, resulting in enhanced ATF2 phosphorylation.
Activated ATF2 dimer binds to CRE site at −461. The two signaling pathways (ATF2 and Smad) converge on the CRE and SBE sites of the Csrp2 promoter
to cooperatively control CRP2 induction in VSMCs, which represents a previously unrecognized mechanism of VSMC gene induction by TGFβ.
Wu et al. Cell Communication and Signaling 2014, 12:22 Page 11 of 14
http://www.biosignaling.com/content/12/1/22of CREB2 and the DNA binding and dimerization domains
of ATF2 was generously provided by G. Thiel (University of
the Saarland Medical Center, Homburg, Germany).
VSMC primary culture and transient transfection assays
Primary VSMCs were isolated from mouse aortas and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) as
described [38]. Cells of passages 5–8 were used for experi-
ments. The day before transfection, approximately 160,000
VSMCs were plated onto each well of 6-well plates. Cells
were then transfected with various luciferase reporter con-
structs (1 μg/well) in triplicates by using FuGENE 6 or X-
tremeGENE 9 according to the manufacturer’s instructions
(Roche). Two hours following transfection, cells were
treated with or without TGFβ (PeproTech, 10 ng/ml).
Luciferase activities were measured 24 h later using
Luciferase Assay System (Promega) and normalized to total
protein content. To evaluate the effect of Smad2 andATF2 on promoter activity, cells were cotransfected
with –795Csrp2-luc (0.33 μg/well) and 0.67 μg/well of ex-
pression plasmid (empty vector, CMV5-Smad2, FLAG-C2/
ATF2, or Smad2 +C2/ATF2) and luciferase activity mea-
sured 24 h later.
For overexpression experiments, VSMCs were electropo-
rated with vector control or expression plasmid Smad2,
C2/ATF2, or Smad2 +C2/ATF2 (8 μg DNA/1 × 106 cells)
with Gene Pulser Xcell™ Electroporation System (Bio-Rad)
using 400 V, 10 ms, square wave parameters. Following re-
covery, cells were serum starved (0.5% FBS in DMEM) and
total RNA or protein isolated at indicated time points for
real time-PCR or Western blot analysis. For dominant-
negative TβRII experiments, VSMCs were electroporated
with pCMV5 vector or pCMV5 HA-TβRII(ΔCyt), serum
starved, treated with or without TGFβ, and then total pro-
teins isolated for Western blot analysis at different time
points.
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To evaluate the effects of TGFβ on protein expressions
and downstream signaling, VSMCs were plated and in-
cubated overnight. Following serum-starvation (0.5%
FBS in DMEM) for 24 h, cells were stimulated with or
without TGFβ. Total proteins were prepared at the in-
dicated time points using extraction buffer containing
protease inhibitor Complete™ (Roche) and Halt™ Phosphat-
ase Inhibitor Cocktail (Thermo Scientific) for Western blot
analysis as described [13]. To inhibit various kinase activ-
ities, VSMCs were treated with inhibitors 30 min prior to
stimulation with or without TGFβ. SB431542 (Calbiochem)
was used for inhibiting TβRI kinase activity, Wortmannin
and LY294002 (Calbiochem) for PI3K, SP600125
(Calbiochem) for JNK, SB203580 (Calbiochem) for p38,
U0126 (Calbiochem) for ERK1/2, Y-27632 (Calbiochem)
for ROCK, and SU6656 (Sigma-Aldrich) for inhibiting
Src family kinase activity.
To assess phosphorylated and total protein of signaling
molecules, membranes were incubated with antibodies
against respective phospho- or total protein. The following
antibodies were purchased from Cell Signaling Technology:
phospho-ATF2 (Thr71, #9221), phospho-Smad2 (Ser465/467,
#3108), phospho-Smad3 (Ser423/425, #9520), Smad2/3
(#3102), phospho-JNK Thr183/Tyr185 (#9251), JNK (#9252),
phospho-p38 Thr180/Tyr182 (#9211), p38 (#9212), phospho-
ERK1/2 Thr202/Tyr204 (#9101), ERK1/2 (#9102), and TβRIII
(#2519). ATF2(C19) antibody (Santa Cruz Biotechnology)
was used to detect total ATF2. CRP2-(91–98) antiserum
[13] was used for CRP2 protein detection. TAK1 and
TRAF6 antibodies (Santa Cruz Biotechnology) were
used to detect TAK1 and TRAF6 expression. To detect
dominant-negative TβRII (HA-TβRII(ΔCyt)) expres-
sion, an anti-HA tag antibody (114-2C-7) (Millipore,
#05-902R) was used. Antibodies TβRI (V-22) (Santa
Cruz Biotechnology), TβRII (L-21) (Santa Cruz Biotechnol-
ogy), and TβRIII (Cell Signaling Technology, #2519) were
used to detect endogenous TβRI, TβRII, and TβRIII expres-
sion, respectively. A mouse monoclonal anti-FLAG anti-
body (Sigma, #F9291) was used to detect FLAG-C2/ATF2
expression. To verify equivalent loading, membranes were
subsequently incubated with an actin antibody (Millipore,
MAB1501).
siRNA knockdown
To suppress mRNA levels of Smad2/3, ATF2, TAK1,
TRAF6, RhoA, TβRI, TβRII, and TβRIII, we performed
knockdown experiments with small interfering RNA
(siRNA). The ON-TARGET plus SMART pool siRNAs
and negative control siRNA were obtained from Dhar-
macon. VSMCs (2.8 x 105 cells) were plated on 60-mm
dish and after overnight incubation, cells were trans-
fected with 20 nM of negative control or target siRNA
in Opti-MEM® I Reduced Serum Medium usingLipofectamine RNAiMAX as described by the manufac-
turer’s protocol (Life Technologies).
Assessment of RhoA activation
RhoA activation was assessed using an Active Rho
Pull-Down and Detection Kit (Thermo Scientific) by
immunoprecipitating GTP-bound RhoA with GST fu-
sion protein of Rhotekin RhoA binding domain (GST-
Rhotekin-RBD). Briefly, VSMCs plated in 150-mm dish
were washed with ice-cold PBS and lysed in buffer contain-
ing 25 mM Tris pH 7.2, 150 mM NaCl, 5 mM MgCl2, 1%
NP-40, and 5% glycerol. Cell lysates (500 μg) were incu-
bated with 400 μg of GST-Rhotekin-RBD and glutathione
resin at 4 °C for 1 h. Following washing, bound Rho was
eluted by SDS sample buffer. The eluted samples and the
total cell lysates were then subjected to Western blot ana-
lysis with RhoA antibody (26C4) (SantaCruz Biotechnology,
sc-418) to detect active and total RhoA, respectively.
Quantitative real time-PCR
Total RNA was isolated using an RNeasy Mini kit (QIA-
GEN) according to the manufacturer’s instructions. One μg
RNA was first reverse transcribed to cDNA with random
primers using SuperScript III reverse transcriptase (Invitro-
gen). Quantitative real time-PCR was performed with the
transcribed cDNA and SYBR® FAST Universal 2X qPCR
Master Mix (KAPA) in triplicates using the 7500 real time
PCR system (Applied Biosystems) to detect CRP2 mRNA
expression. The primers used for CRP2 are: forward,
5′-CTGACTGAGAAAGAAGGCGAAATC-3′ and re-
verse, 5′-TGCTGGCTGTTTCACAGTAGTGA-3′. β-
actin was used as an internal control for normalization with
the following primers: forward, 5′-GAGAGGTATCCT-
GACCCTGAAG-3′; reverse, 5′-TGATCTGGGTCATCTT
TTCACGG-3′. Quantification was performed by the com-
parative CT method.
Statistical analysis
Data are presented as mean ± S.E. of at least three inde-
pendent experiments. All results were analyzed statisti-
cally by Student’s t-test. P values <0.05 are considered
statistically significant.
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